SHORT ANSWER MANAGEMENT POP QUIZ (answers below)
1. Name THREE classes of HIV treatment medications.
2. How would you counsel a patient who is HIV positive, and on treatment, who asks you about how HIV will limit their life expectancy?
Did you know Saskatchewan HIV rates are 2 times the national average?
THE CHALLENGE IN SASKATCHEWAN
You may have seen the headlines on the CBC about the HIV crisis in Saskatchewan. HIV treatment, diagnosis and care is increasingly a part of the spectrum of care for family physicians across the country in both rural and urban environments. As HIV/AIDS patients live longer they are shifting the demographics of the disease and their incidence of CVD, non-HIV related cancer, and renal and hepatic impairment is greater than those of uninfected individuals of the same age.
DID YOU KNOW – Life expectancy of HIV-infected individuals is near normal.
1. a) Nucleoside/nucleotide reverse transcriptase inhibitors [Zidovudine]
b) Non-nucleoside reverse transcriptase inhibitors [Nevirapine]
c) Protease inhibitors [Ritinovir]
d) Integrase inhibitors [Elvitegravir]
e) CCR5 (C-C chemokine receptor type 5) receptor antagonist [Maraviroc]
f) Fusion inhibitor [Enfuvirtide]
EXAM TIP - At The Review Course we have a few mantras that we say again and again to get you ready to ace the exam. One tip is to ensure that you have an HIV-Free exam. What does that even mean? During your exam, before you click close and walk out of the exam room to your freedom, review your paper patients and SOO patients and take a moment to think; did I miss a screening opportunity or a potential HIV/AIDS patient??
Christine A. Hughes, BScPharm PharmD, Alice Tseng, BScPhm PharmD, Ryan Cooper. Managing drug interactions in HIV-infected adults with comorbid illness. CMAJ January 6, 2015 vol. 187 no. 1 First published September 15, 2014, doi: 10.1503/cmaj.131626
REGISTRATION OPEN! The Review Course Winter 2017 is open now and selling fast!
See our registration page for more details and make sure you sign up before we sell out in 2017!